A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

About This Trial

This study looks at how consistently patients take a daily prescription medicine called apalutamide during their first year of treatment.
It is for men with advanced prostate cancer that still responds to hormone therapy who, along with their doctor, have already decided to start taking apalutamide for the first time.
Researchers want to understand everyday routines and personal challenges that might make it difficult for people to take their pills as prescribed.
Because this study tracks standard care rather than testing a brand-new drug, participating mainly involves answering regular questionnaires about your medication habits and your overall quality of life.

This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.

Age Range: 18 years and older
Gender: Male
Who This Trial is For: This study looks at how consistently patients take a daily prescription medicine called apalutamide during their first year of treatment.

Full Eligibility Criteria

Inclusion Criteria

Male (based on chromosomal composition at birth) and aged greater than or equal to (>=) 18 years.
Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)
Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy [ADT]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion
Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection
Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.
Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide

Exclusion Criteria

Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC
Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection
Is currently receiving active treatment for prostate cancer as part of an interventional study
Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment
Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment
Beneficiary of State Medical Aid [AME]
Does not speak/read French
Under guardianship or curatorship
Under judicial protection